Psychological Factors Affecting Response to Antidepressant Drugs in Fibromyalgia

Psychosomatics

Volumn 52, Issue 3, 2011, Pages 237-244

  Díaz Marsá, Marina ^a,b   Palomares, Nerea ^b   Morón, M Dolores ^a   Tajima, Kazuhiro ^a   Fuentes, Manuel E ^a   López Ibor, Juan José ^a,b   Carrasco, José Luis ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE; NARCOTIC ANALGESIC AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; DELAYED RELEASE FORMULATION; LEIOMYOMA; MAJOR DEPRESSION; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LEIOMYOMA; MALE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 80052878626     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2010.12.014     Document Type: Article

References (34)

1. Rossy L.A., Buckelew S., Dorr N., et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behavioural Med 1999, 21:180-191.
2. Sumpton J.E., Moulin D.E. Fibromyalgia: Presentation and management with a focus on pharmacological treatment. Pain Res Manag 2008, 13:477-483.
3. Offenbaecher M., Glatzeder K., Ackenheil M. Self-reported depression, familiar history of depression and fibromyalgia (FM), and psychological distress in patients with FM. Z Rheumatology 1998, 57:94-96.
4. Lucas H.J., Brauch C.M., Settas L., et al. Fibromyalgia. New concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006, 19:5-9.
5. Hughes L. Physical and psychological variables that influence pain in patients with fibromyalgia. Orthop Nurs 2006, 25:112-119.
6. Abeles M., Solitar B.M., Pillinger M.H., et al. Update on Fibromyalgia Therapy. Am J Med 2008, 121:555-561.
7. Goldenberg D.L., Burckhardt C., Crofford L. Management of fibromyalgia syndrome. J Am Med Assoc 2004, 292:2388-2395.
8. Rivera J. Tratamiento farmacológico de la fibromialgia. Inf Ter Del Sistema Nacional de Salud 2008, 32:107-115.
9. Arnold L.M. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8:212-232.
10. Moret C., Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treatment 2006, 2:537-548.
11. Kassis A. Antidepressants to treat nonspecific low back pain. Cochrane for Clinicians. American Family Physician 2008, 78:51-52.
12. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005, 32:1975-1985.
13. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
14. Dwight M.M., Arnold L.M., O'Brien H., et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998, 39:14-17.
15. Wolfe F., Smythe H., Yunas M., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990, 33:160-172.
16. First M.B., Spitzer R.L., Gibbon M., et al. Structured Clinical Interview for the DSM-IV Axis I Disorders-patient edition (SCID-I/P, ver. 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
17. Burckhardt C.S., Clark S.R., Bennett R.M. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991, 18:728-733.
18. Hudson J.I., Goldenberg D.L., Pope H.G., et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992, 92:363-367.
19. Hudson J.I., Pope H.G. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996, 22:285-303.
20. Thieme K., Turk D.C., Flor H. Omorbid depression and anxiety in fibromyalgia syndrome: Relationship to somatic and psychosocial variables. Psychosom Med 2004, 66:837-844.
21. Henriksson C., Gundmark I., Bengtsson A., et al. Living with fibromyalgia. Consequences for everyday life. Clin J Pain 1992, 8:138-144.
22. Mease P.J., Clauw D.J., Gendreau R.M., et al. The efficacy and safety of minalcipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:398-409.
23. Vitton O., Gendreau M., Gendreau J., et al. A doubled-blind placebo-controlled trial of minalcipran in the treatment of fibromialgia. Hum Psychopharmacol Clin Exp 2004, 19:S27-S35.
24. Arnold L.M., Clauw D.J., Wohlreich M.M., et al. Efficacy of duloxetine in patients with fibromyalgia: Pooled analysis of four placebo-controlled clinical trials. Primary Care Companion. J Clin Psychiatry 2009, 11:237-244.
25. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
26. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
27. Chappell A.S., Bradley L.A., Wiltse C., et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J General Med 2008, 1:91-102.
28. Fishbain D. Evidence-based data on pain relief with antidepressants. Annal Med 2000, 32:305-316.
29. Geisser M.E., Strader C., Petzke F., et al. Comorbid somatic symptoms and functional status in patients with fibromyalgia and chronic fatigue syndrome: Sensory amplification as a common mechanism. Psychosomatics 2008, 49:235-242.
30. Kurland J., Coyle W., Winkler A., et al. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Digestive Dis Sci 2006, 51:454-460.
31. Munce S.E.P., Stewart D.E. Gender differences in depression and chronic pain conditions in a national epidemiologic survey. Psychosomatics 2007, 48:394-399.
32. González E., Elorza J., Failde I. Fibromyalgia and psychiatric comorbidity: Their effect on the quality of life of patients affected. Acta Esp Psiquiatría 2009, in press.
33. Tunks E.R., Crook J., Weir R. Epidemiology of chronic pain with psychological comorbidity: Prevalence, risk, course, and prognosis. Can J Psychiatry 2008, 53:224-234.
34. García-Campayo J., Magdalena J., Magallón R., et al. A meta-analysis of the efficacy of fibromyalgia treatment according to level of care. Arthritis Res Ther 2008, 10:R81.